an emerging leader in hematology/oncology and are committed to making a profound impact in the lives of patients - with the ongoing commercialization of Monjuvi® and the clinical development of pelabresib in myelofibrosis.
Since launch, approximately 2,000 patients have been treated with our cancer immunotherapy in the U.S. Monjuvi, in combination with lenalidomide, provides a paradigm shift in treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Beyond the current indication, approved under accelerated approval, we are developing Monjuvi in additional hematological indications.
Our aspiration for our most exciting new pipeline asset is to potentially change the standard of care in myelofibrosis, a bone marrow cancer for which only limited treatment options are available. Pelabresib is currently being explored in a phase 3 trial, and we expect the data in the first half of 2024.